24 completed, 7 unknown, 4 active not recruiting, 4 terminated. 25 Phase 2, 6 Phase 1, 2 Not applicable, 2 Phase 3, 1 Early Phase 1.
Follow Recurrent Cervical Carcinoma: new trials by email Literature Review of Recurrent Cervical Carcinoma trials Research Report on Recurrent Cervical Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer PRGN-2009 plus Pembrolizumab - Cervical Cancer, HPV-Related Carcinoma | Phase 2 | Recruiting | Precigen, Inc | 24 | 2025-11-11 | 2026-04-23 |
| Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform Biospecimen Collection, Tissue Collection - Early Stage Triple-Negative Breast Carcinoma, Metastatic Bladder Urothelial Carcinoma | Recruiting | Mayo Clinic | 324 | 2024-04-24 | 2026-03-12 | |
| Dostarlimab and Cobolimab in Advanced Cervical Cancer Dostarlimab, Cobolimab - Cervical Cancer, Advanced Cervical Carcinoma | Phase 2 | Active not recruiting | Meghan Shea | 66 | 2024-03-11 | 2026-01-13 |
| Tislelizumab and Radiotherapy for Recurrent Cervical Cancer Tislelizumab plus radiotherapy - Recurrent Cervical Carcinoma, Metastatic Cervical Carcinoma | Phase 2 | Unknown | Lei Li | 58 | 2022-03-27 | 2022-04-11 |
| Donafenib for Recurrent Cervical Cancer Donafenib combined with paclitaxel and platinum ± PD-1 antibody - Targeted Therapy, Chemotherapy | Phase 2 | Unknown | Lei Li | 20 | 2022-03-27 | 2022-04-04 |
| PD-1 Antibody and Radiotherapy for Recurrent Cervical Cancer Radiotherapy for targeted lesions and PD-1 antibody - Immune Checkpoint Inhibitors, Anti-programmed Death-1 Antibody | Unknown | Lei Li | 20 | 2022-03-26 | 2022-04-11 | |
| Immunotherapy for Recurrent Cervical Cancer Refractory to Platinum-based Chemotherapy: Multi-Center Trial Anti-PD-1 antibody camrelizumab, Albumin-bound paclitaxel - Recurrent Cervical Carcinoma, Persistent Advanced Cervical Carcinoma | Phase 2 | Unknown | Lei Li | 122 | 2022-03-13 | 2022-03-22 |
| Combination of Nimotuzumab and Radiotherapy for Recurrent Uterine Cervical Squamous Carcinoma Combination of nimotuzumab and radiotherapy - Recurrent Cervical Carcinoma, Radiotherapy | Phase 2 | Unknown | Lei Li | 43 | 2020-12-19 | 2020-12-22 |
| Human Papilloma Virus (HPV) Circulating Tumor DNA (ctDNA) in Cervical Cancer Biospecimen Collection - Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified | Active not recruiting | Mayo Clinic | 18 | 2020-11-17 | 2025-10-27 | |
| Camrelizumab Combined With Chemotherapy for Recurrent or Advanced Cervical Neuroendocrine Carcinomas Drug therapy - Chemotherapy, Anti-pd-1 Antibody | Phase 2 | Unknown | Lei Li | 20 | 2020-11-15 | 2020-11-19 |
| Immunotherapy for Recurrent Cervical Cancer Refractory to Platinum-based Chemotherapy A combination of anti-PD-1 antibody camrelizumab and albumin-bound paclitaxel - Recurrent Cervical Carcinoma, Persistent Advanced Cervical Carcinoma | Phase 2 | Completed | Lei Li | 34 | 2019-12-06 | 2022-03-15 |
| First-line Chemotherapy for Recurrent Cervical Cancer Chemotherapy plus apatinib - Recurrent Cervical Carcinoma, Persistent Advanced Cervical Carcinoma | Phase 2 | Completed | Lei Li | 37 | 2019-12-06 | 2022-03-15 |
| Paclitaxel Therapeutic Drug Monitoring in Cancer Patients Blood draws, QLQ-CIPN20 Survey, PR-CTCAE Survey - Solid Tumor, Adult, Metastatic Nonsmall Cell Lung Cancer | Suspended | Wake Forest University Health Sciences | 55 | 2019-11-11 | 2026-08-13 | |
| Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers Quality-of-Life Assessment, Radiation Therapy, Talazoparib - Malignant Female Reproductive System Neoplasm, Recurrent Cervical Carcinoma | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 24 | 2019-09-26 | 2026-03-11 |
| SHR-1210 in Combination With Apatinib in Patients With Metastatic, Persistent, or Recurrent Cervical Cancer SHR-1210, Apatinib - Recurrent Cervical Carcinoma, Metastatic Cervical Cancer | Phase 2 | Completed | Sun Yat-sen University | 45 | 2019-01-19 | 2023-04-11 |
| DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine MEDI0457, Durvalumab - Human Papillomavirus-16 Positive, Human Papillomavirus-18 Positive | Phase 2 | Terminated | M.D. Anderson Cancer Center | 41 | 2018-11-14 | 2024-07-09 |
| Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis Ipilimumab, Laboratory Biomarker Analysis, Nivolumab - Malignant Peritoneal Neoplasm, Malignant Retroperitoneal Neoplasm | Phase 1 | Completed | M.D. Anderson Cancer Center | 26 | 2018-09-21 | 2025-05-22 |
| Stereotactic Body Radiation Therapy, Tremelimumab and Durvalumab in Treating Participants With Recurrent or Metastatic Cervical, Vaginal, or Vulvar Cancers Durvalumab, Laboratory Biomarker Analysis, Stereotactic Radiosurgery - Advanced Cervical Adenocarcinoma, Advanced Vaginal Carcinoma | Phase 1 | Completed | M.D. Anderson Cancer Center | 20 | 2018-07-18 | 2023-09-13 |
| Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer Durvalumab, Tremelimumab, Radiation Therapy - Recurrent Gynecological Cancer, Metastatic Cervical Cancer | Phase 1 | Terminated | Dana-Farber Cancer Institute | 16 | 2018-06-01 | 2025-05-31 |
| Testing AZD1775 inC Combination With Radiotherapy and Chemotherapy in Cervical, Upper Vaginal and Uterine Cancers Adavosertib, Cisplatin, External Beam Radiation Therapy - Cervical Carcinoma, Endometrioid Adenocarcinoma | Phase 1 | Terminated | National Cancer Institute (NCI) | 10 | 2018-05-29 | 2024-02-20 |
Showing 20 of 43. Sign in to see all of them.
Uterine Cervical Neoplasms (43) · Ovarian Neoplasms (8) · Endometrial Neoplasms (6) · Vaginal Neoplasms (6) · Vulvar Neoplasms (6) · Breast Neoplasms (3) · Carcinoma, Renal Cell (3) · Fallopian Tube Neoplasms (3) · Uterine Neoplasms (3) · Carcinoma, Hepatocellular (2) · Carcinoma, Non-Small-Cell Lung (2) · Colorectal Neoplasms (2) · Esophageal Neoplasms (2) · Lung Neoplasms (2) · Melanoma (2)
Female Urogenital Diseases (43) · Female Urogenital Diseases and Pregnancy Complications (43) · Genital Diseases (43) · Genital Diseases, Female (43) · Genital Neoplasms, Female (43) · Neoplasms by Site (43) · Urogenital Diseases (43) · Urogenital Neoplasms (43) · Uterine Cervical Diseases (43) · Uterine Diseases (43) · Neoplasms (42) · Uterine Neoplasms (40) · Adnexal Diseases (9) · Endocrine System Diseases (9) · Gonadal Disorders (9)
Disulfides (5) · Immunoglobulin G (5) · Paclitaxel (5) · Radiotherapy (5) · Taxes (5) · 1,2-diaminocyclohexaneplatinum II citrate (4) · Cisplatin (4) · Platinum (4) · Albumin-Bound Paclitaxel (3) · Nivolumab (3) · Topotecan (3) · durvalumab (3) · Bevacizumab (2) · Blood Specimen Collection (2) · CTLA-4 Antigen (2)
Gynecologic Oncology Group (10) · National Cancer Institute (NCI) (10) · Lei Li (8) · M.D. Anderson Cancer Center (4) · Mayo Clinic (3) · Sun Yat-sen University (2) · Albert Einstein College of Medicine (1) · Dana-Farber Cancer Institute (1) · Meghan Shea (1) · Precigen, Inc (1) · University of Washington (1) · Wake Forest University Health Sciences (1)
United States (32) · China (10) · Canada (4) · Spain (2) · Guam (1) · Hong Kong (1) · Puerto Rico (1)
Lei Li, M.D. (8) · Lilie L Lin (2) · Agustin Garcia (1) · Alessandro D Santin (1) · Alessandro Santin (1) · Allison E. Garda, MD (1) · Amir A Jazaeri (1) · Amit M Oza (1) · Anna Tinker (1) · Bradley Monk (1) · Charles Kunos (1) · Claire F Friedman (1) · D. McMeekin (1) · David Alberts (1) · Dennis Kuo (1)
PMID 19931137, PMID 24552320, PMID 25638326, PMID 25937529, PMID 26586415, PMID 27998970, PMID 28728751, PMID 28756902, PMID 31924334, PMID 32463741, PMID 32641240, PMID 32847980, PMID 33004542, PMID 33048619, PMID 33052760, PMID 34011535, PMID 35133871, PMID 35138919, PMID 36115931, PMID 36351402, PMID 36898292, PMID 37053535, PMID 37322121, PMID 37934000, PMID 38471508, PMID 38591867, PMID 39666929, PMID 39693587, PMID 39913886, PMID 40273550, PMID 40791544, PMID 40865033, PMID 41066729, PMID 41484629
U10CA027469 (11), U10CA180868 (6), P30CA013330 (2), N01CM00032 (1), N01CM00038 (1), N01CM00071 (1), N01CM62204 (1), P30CA012197 (1), P30CA015083 (1), R01CA155454 (1), U10CA101165 (1), U10CA180820 (1), U10CA180821 (1), U10CA180830 (1), U24CA196172 (1)